Brought to you by 
Amylin, J&J's LifeScan to develop AC137 for diabetes
24 May 2013
Executive Summary
J&J's LifeScan diabetes unit signed a $70+mm collaboration to develop and commercialize Amylin's hormone analog AC137 (pramlintide) for treating insulin-using patients with Type I or II diabetes. The two will share costs, profits, and rights 50/50.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Disease Management
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com